Cargando…
Aberrant splicing and drug resistance in AML
The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events have been recognized as a prominent component of this disease....
Autores principales: | de Necochea-Campion, Rosalia, Shouse, Geoffrey P., Zhou, Qi, Mirshahidi, Saied, Chen, Chien-Shing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018179/ https://www.ncbi.nlm.nih.gov/pubmed/27613060 http://dx.doi.org/10.1186/s13045-016-0315-9 |
Ejemplares similares
-
Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest
por: Shouse, Geoffrey, et al.
Publicado: (2016) -
Metastatic biomarkers in synovial sarcoma
por: de Necochea-Campion, Rosalia, et al.
Publicado: (2017) -
Aberrant RNA Splicing in Cancer and Drug Resistance
por: Wang, Bi-Dar, et al.
Publicado: (2018) -
A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014) -
Expression of the Epigenetic factor BORIS (CTCFL) in the Human Genome
por: de Necochea-Campion, Rosalia, et al.
Publicado: (2011)